Advanced Search: Relapsed/Refractory

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201907126

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

202107168

Phase 1 trial of the LSD1 Inhibitor Seclidenstat (SP-2577) with and without Topotecan and Cyclophosphamide in patients with relasped or refractory Ewing Sarcoma and select Sarcomas

202108106

A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma

202112016

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

201709159

A Phase III Study of AL3818 (Catequentinib,Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

202003170

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors

202001168

A Phase 2, Single-Arm Open-Label Study of Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as having CDK Pathway Alteration

202202093

A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

202002113

A Phase II Study of Cabozantinib and Temozolomide in Patients with Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

202012066

A PHASE Ib /II STUDY OF APG-115 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMAS OR ADVANCED SOLID TUMORS